The U.S. organ-on-a-chip market size was estimated at USD 71.7 million in 2024 and is projected to reach USD 940.4 million by 2033, growing at a CAGR of 33.14% from 2025 to 2033. This growth is driven by increasing demand for more predictive preclinical testing models, a shift from animal testing, and rapid advancements in microfluidics, tissue engineering, and personalized medicine.
As pharmaceutical companies, biotech firms, and research institutions seek more accurate, ethical, and cost-effective ways to study human physiology and disease, organ-on-a-chip technologies are gaining traction as a transformative solution across the biomedical landscape.
The integration of stem cell technology, particularly induced pluripotent stem cells (iPSCs), further enhances the value of OOC platforms by allowing the development of patient-specific models. These personalized chips can reflect genetic variations and disease phenotypes unique to individuals, supporting precision medicine approaches. Moreover, recent innovations have allowed multiple organ systems to be connected on a single chip, enabling researchers to study how drugs or diseases affect the body rather than in isolation. This convergence of engineering and biology fuels sustained demand across the pharmaceutical, biotech, and academic research.
This product will be delivered within 2 business days.
As pharmaceutical companies, biotech firms, and research institutions seek more accurate, ethical, and cost-effective ways to study human physiology and disease, organ-on-a-chip technologies are gaining traction as a transformative solution across the biomedical landscape.
Advancements in Microfluidics & Tissue Engineering
Advancements in microfluidics and tissue engineering have become a foundational driver of growth in the U.S. organ-on-a-chip industry. Microfluidic technologies enable precise control over the flow of nutrients, drugs, and mechanical stimuli at a microscale, closely mimicking the dynamic conditions of the human body. Tissue engineering complements this by enabling the creation of 3D cellular structures using human-derived cells, which can be designed to functionally resemble specific organs like the liver, lung, heart, or gut. These innovations have significantly improved the physiological relevance of preclinical testing, offering researchers more predictive and ethically responsible tools for studying disease and drug response.The integration of stem cell technology, particularly induced pluripotent stem cells (iPSCs), further enhances the value of OOC platforms by allowing the development of patient-specific models. These personalized chips can reflect genetic variations and disease phenotypes unique to individuals, supporting precision medicine approaches. Moreover, recent innovations have allowed multiple organ systems to be connected on a single chip, enabling researchers to study how drugs or diseases affect the body rather than in isolation. This convergence of engineering and biology fuels sustained demand across the pharmaceutical, biotech, and academic research.
U.S. Organ-on-a-Chip Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. The analyst has segmented the U.S. organ-on-a-chip market report based on the product & service, application, and end-use:Product & Service Outlook (Revenue, USD Million, 2021-2033)
- Products
- Instrument
- Devices
- Liver-on-a-Chip
- Lung-on-a-Chip
- Intestine-on-a-Chip
- Kidney-on-a-Chip
- Heart-on-a-Chip
- Others
- Services
Application Outlook (Revenue, USD Million, 2021-2033)
- Drug Discovery
- Toxicology Research
- Others
End-use Outlook (Revenue, USD Million, 2021-2033)
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Others
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variables, Trends, & Scope
Chapter 4. Product & Service Group Business Analysis
Chapter 5. Application Group Business Analysis
Chapter 6. End Use Business Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies profiled in this U.S. Organ-on-a-Chip market report include:- Emulate, Inc.
- MIMETAS B.V.
- Valo Health
- Quris Technologies LTD. (Nortis, Inc.)
- AxoSim
- BICO - THE BIO CONVERGENCE COMPANY
- CN Bio Innovations Ltd
- The Charles Stark Draper Laboratory, Inc.
- SynVivo, Inc.
- AlveoliX AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 110 |
| Published | August 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 71.7 Million |
| Forecasted Market Value ( USD | $ 940.4 Million |
| Compound Annual Growth Rate | 33.1% |
| Regions Covered | United States |
| No. of Companies Mentioned | 11 |
